KROS at a glance
Keros Therapeutics, Inc. (KROS, SEC CIK 1664710) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Keros Therapeutics, Inc. (KROS) reported revenue of $244.1 million (up 6775.0% from FY2024) and net income of $87.0 million. Diluted EPS was $2.30.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Keros Therapeutics, Inc. (KROS) shares worth $93.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Newton Charles W. on August 18, 2026 of 551 shares at $10.30 per share.
- In the last 90 days, KROS insiders reported 2 open-market purchases ($21K) and 4 open-market sales ($101K) on Form 4, a net sale of $80K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $244.1M
- +6775.0% vs prior year
- Insiders · 90 days
- 2 buys · 4 sells
- Net −$80K
- 13F holders
- 26 funds
- $93.7M · −1 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0 vs $18.2M YoY, down $18.2M from Takeda service revenue
- Net loss $28.7M vs $30.7M YoY; operating loss $30.9M vs $39.8M
- Rinvatercept R&D $4.1M, up $2.7M; elritercept $14K, down $15.6M
- Cash and equivalents $257.6M as of June 30, 2026
- Near-term headwinds: inflation, higher rates, tariffs, supply-chain constraints and geopolitical uncertainty
Risk Factors
- Net loss $52.4 million for six months ended June 30, 2026, with accumulated deficit of $534.2 million
- Cash $257.6 million, expected to fund operations into first half of 2028
- Clinical-trial risk heightened by prior TROPOS termination after pericardial effusion safety events
- Regulatory approval risk from FDA disagreement over trial design, endpoints, or clinical-data interpretation
- Near-term execution risk from Phase 2 rinvatercept trials in Duchenne muscular dystrophy and planned ALS initiation
AI summary of the KROS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- $20 million development milestone payable to Keros following first-patient dosing in elritercept’s ELRiSE MF trial
- ELRiSE MF advancement into Phase 3 supports elritercept’s progression toward potential myelofibrosis approval
Item 7.01: Regulation FD Disclosure
- Phase 2 trial of rinvatercept initiated in Duchenne muscular dystrophy
- First patient dosed on September 28, 2026, marking clinical development advancement
Item EX-99.1: Item EX-99.1
- First patient dosed in Phase 2 rinvatercept trial for Duchenne muscular dystrophy, advancing Keros’ lead neuromuscular program
- Initial trial data expected in first half of 2027, establishing the next major clinical catalyst
Item 8.01: Other Events
- Board authorized repurchases of up to $5 million in common stock following Takeda’s $20 million development milestone payment
- Cash and equivalents totaled $257.6 million as of June 30, 2026
Item EX-99.1: Item EX-99.1
- $5 million share repurchase authorization following $20 million elritercept milestone payment from Takeda
- Repurchases may occur in open-market transactions or other lawful methods
AI summaries of KROS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KROS
Don't miss the next KROS filing
- Alerts as it files. A push when KROS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KROS, by share count.
- Ask anything. An AI agent that reads every KROS filing and answers with sources.
KROS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Newton Charles W. | Sell | Aug 18, 2026 | 551 | $10.30 |
| Tanini Annita | Sell | Aug 18, 2026 | 1,224 | $10.29 |
| Cho Esther | Sell | Aug 18, 2026 | 4,485 | $10.29 |
| Lerner Lorena Raquel | Sell | Aug 18, 2026 | 3,568 | $10.29 |
| BIENAIME JEAN JACQUES | Buy | Aug 17, 2026 | 1,000 | $10.27 |
| BIENAIME JEAN JACQUES | Buy | Jul 15, 2026 | 1,000 | $10.61 |
| Prener Anne | A | Jul 1, 2026 | 13,786 | - |
| Prener Anne | A | Jul 1, 2026 | 14,870 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $151K | $3.5M | $244.1M |
| Operating Income | - | -$210.8M | $67.6M |
| Net Income | -$153.0M | -$187.4M | $87.0M |
| Op. Margin | - | -5939.0% | 27.7% |
| Net Margin | -101319.2% | -5277.5% | 35.7% |
| Balance Sheet | |||
| Total Assets | - | $615.9M | $338.0M |
| Equity | - | $571.6M | $303.1M |
| ROE | - | -32.8% | 28.7% |
| Per Share | |||
| EPS | $-5.20 | $-5.00 | $2.30 |
| Cash Flow | |||
| Operating CF | - | -$160.9M | $107.5M |
| CapEx | $2.5M | $1.9M | $1.6M |
Source: XBRL data in Keros Therapeutics, Inc. (KROS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KROS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $93.7M |
| Q1 2026 | 27 | $92.4M |
| Q4 2025 | 24 | $190.2M |
| Q3 2025 | 25 | $190.5M |
| Q2 2025 | 26 | $153.5M |
| Q1 2025 | 20 | $124.2M |
| Q4 2024 | 15 | $191.5M |
| Q3 2024 | 14 | $216.6M |
- AQR Capital Management+561.3K (+138%)
- BlackRock+382.4K (+16%)
- Dimensional Fund Advisors+139.2K (+43%)
- Millennium Management+78.0K (+73%)
- T. Rowe Price Group+10.2K (+22%)
- D.E. Shaw & Co−242.1K (-48%)
- Two Sigma Investments−117.2K (-32%)
- Northern Trust−100.3K (-39%)
- Renaissance Technologies LLC−94.4K (-21%)
- Goldman Sachs Group−46.6K (-21%)
- Franklin Resources−21.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KROS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
KROS SEC filings: frequently asked questions
Are KROS insiders buying or selling?
In the last 90 days, Keros Therapeutics, Inc. (KROS) officers, directors and 10% owners reported 2 open-market purchases worth $20,880 by 1 insider and 4 open-market sales worth $101,136 by 4 insiders on Form 4, a net sale of $80,256. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KROS stock?
As of June 30, 2026, the largest Keros Therapeutics, Inc. (KROS) holders among the 13F filers tracked by SignalX were BlackRock ($29.9 million), AQR Capital Management ($10.4 million), Vanguard Capital Management LLC ($8.9 million), Vanguard Portfolio Management LLC ($7.0 million), State Street Corp ($5.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KROS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Keros Therapeutics, Inc. (KROS) reported revenue of $244.1 million (up 6775.0% from FY2024) and net income of $87.0 million. Diluted EPS was $2.30. The figures come from the XBRL data in the 10-K.
What did KROS report in its latest 8-K?
Keros Therapeutics, Inc. (KROS) filed an 8-K on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure). $20 million development milestone payable to Keros following first-patient dosing in elritercept’s ELRiSE MF trial.
What are the latest KROS SEC filings?
Keros Therapeutics, Inc. (KROS) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on August 20, 2026.
What is KROS's SEC CIK number?
Keros Therapeutics, Inc. (KROS)'s SEC Central Index Key (CIK) is 1664710. EDGAR lists every KROS filing under that number.
Ask anything about KROS
The research agent reads KROS's filings, financials, insider trades and 13F holders, then answers with sources.